Table 4.

Viral responses to EBV-specific T cells

Pt. no.	Viral disease	Previous standard therapy	Line infused	HLA match (low-resolution) to recipient	No. of infusions	Best response by 6 wk	Comments
16	EBV	Rituximab (tumor later found to be CD20 negative)	C2274	2/6	3	CR	CR EBV-PTLD based on imaging
19	EBV	Rituximab	C3366 C2270	2/6	3	PR	CR based on viral load PR peripheral disease and stable CNS disease at 5 wk based on imaging when removed from study because of relapse of AML
				1/6
24	EBV	Rituximab	C3629	1/6	1	NR	Decrease in EBV-DNA followed by a chronic GVHD flare treated with steroids. Died of EBV lymphoma
37	EBV	Rituximab	C3617	3/6	1	CR	CR EBV-PTLD based on imaging
43	EBV	Rituximab	C3005	1/6	1	PR	Very good PR based on imaging
47*	EBV (AdV)	Rituximab	C2339 (C2654)	1/6	5 (1)	PR (CR)	Five infusions for EBV-PTLD with CR after 6 wk based on imaging and viral loads (subsequent emergency use of VST infusion for AdV followed by CR)
				(1/6)
74	EBV	Rituximab	C3365 C2582	3/6	2	NR	Died of EBV lymphoma. Second line administered after confirming EBV-PTLD origin was in second, not first, CBU
				1/6
79	EBV	Rituximab	C3617	2/6	3	PR	Transient PRs then recurrences, subsequent CR by viral load after infusion of donor-derived EBV-specific T cells
90	EBV	Rituximab	C2339	3/6	1	NR	Died of EBV lymphoma

AML, acute myeloid leukemia; CBU, cord blood unit; CNS, central nervous system. Other previously used abbreviations are explained in Table 2.

^*Subsequently went on to have an AdV infection and received a different VST line as emergency treatment after approval by the US Food and Drug Administration.